Nottingham, UK – 19th September 2019 – The space occupied by a drug molecule in three dimensions, and how it fits into the target, is an important consideration when designing a new compound that might become a drug. Medicinal chemists commonly use 3D rendering software to visualise the shape of molecules by creating chemical structures they... Read more
Nottingham, UK – 15 February 2019 – Sygnature Discovery, the leading independent integrated drug discovery and pre-clinical services provider, have made two key appointments. Dr Allan Jordan and Ms Louisa Jordison have joined the organisation as they continue their strong growth trajectory in the drug research market. Allan comes on-board as Director of Oncology Drug... Read more
Nottingham, UK / Cambridge, MA – 27 November 2018 – Sygnature Discovery a leading independent integrated drug discovery and pre-clinical services company, is continuing the expansion of its operations with the opening of its first US office, located in Harvard Square, Cambridge, Massachusetts. Since its inception in 2004, Sygnature has worked closely with a range... Read more